Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
DC CAFCFirst Claim
Patent Images
1. An isolated monoclonal antibody, wherein, when bound to PCSK9, the monoclonal antibody binds to at least one of the following residues:
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
-
Citations
29 Claims
-
1. An isolated monoclonal antibody, wherein, when bound to PCSK9, the monoclonal antibody binds to at least one of the following residues:
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
-
17. A pharmaceutical composition comprising an isolated monoclonal antibody, wherein, when bound to PCSK9, the isolated monoclonal antibody binds to at least one of the following residues:
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.
- S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO;
-
29. A pharmaceutical composition comprising an isolated monoclonal antibody, wherein the isolated monoclonal antibody binds to at least two of the following residues S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of PCSK9 listed in SEQ ID NO:
- 3 and blocks the binding of PCSK9 to LDLR by at least 80%.
Specification